Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.61 |
| ▸ | MAOB | P27338 | 7/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.54 |
| ▸ | CCR3 | P51677 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14411640 | 0.98 | HTR7 (0.58) | HTR7MAOBMAOAALDH1A1SMN1; SMN2 | |
| SCHEMBL5446903 | 0.94 | CREBBP (0.56) | HTR7MAOBALDH1A1SMN1; SMN2CREBBP | |
| SCHEMBL5452082 | 0.88 | L3MBTL1 (0.57) | HTR7KCNH2CNR2 | |
| SCHEMBL5454517 | 0.85 | CNR2 (0.54) | ALDH1A1SMN1; SMN2CREBBPCNR2 | |
| SCHEMBL5450951 | 0.85 | HTR7 (0.55) | HTR7CCR3SIGMAR1CNR2 | |
| SCHEMBL14412209 | 0.83 | HTR7 (0.52) | HTR7MAOBALDH1A1KCNH2CNR2 | |
| SCHEMBL14411316 | 0.83 | KAT2B (0.58) | HTR7CREBBP | |
| SCHEMBL14463824 | 0.83 | CNR2 (0.57) | HTR7ALDH1A1SMN1; SMN2CREBBPCNR2 | |
| SCHEMBL5448708 | 0.83 | SMN1; SMN2 (0.55) | ALDH1A1SMN1; SMN2CREBBPCNR2 | |
| SCHEMBL5448736 | 0.83 | KCNH2 (0.60) | ALDH1A1SMN1; SMN2KCNH2CREBBPCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | HTR7 269/4885MAOB 1224/4885MAOA 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.